Vogenx (NASDAQ:VOGX) Upgraded at Zacks Research

Vogenx (NASDAQ:VOGX) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen upgraded Vogenx to a “hold” rating in a research note on Saturday, August 22nd. JonesTrading began coverage on shares of Vogenx in a research report on Tuesday, September 1st. They issued a “buy” rating and a $55.00 price target on the stock. Finally, WBB Securities started coverage on shares of Vogenx in a report on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $48.50.

Vogenx Stock Performance

Shares of NASDAQ VOGX opened at $24.32 on Monday. Vogenx has a 1-year low of $12.95 and a 1-year high of $38.41.

Vogenx (NASDAQ:VOGX) last issued its earnings results on Thursday, September 17th. The company reported ($0.07) earnings per share (EPS) for the quarter. Analysts expect that Vogenx will post -0.61 EPS for the current fiscal year.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.